Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The efficacy of preoperative transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) remains unclear. This study aimed to investigate the impact of preoperative TACE for resectable solitary HCC.
Methods: This retrospective study included 4899 patients who underwent hepatectomy from 2008 to 2019. Survival outcomes were compared before and after propensity score matching (PSM) based on tumor size (≤ 3, 3-5, and > 5 cm) between the preoperative TACE (n = 378) and upfront surgery groups (n = 4521). Cox regression analysis was utilized to identify predictors of overall survival (OS) and recurrence-free survival (RFS).
Results: For HCC ≤ 3 cm, OS was similar between the groups but RFS significantly improved in the preoperative TACE group both before (OS: p = 0.44; RFS: p < 0.001) and after (OS: p = 0.84; RFS: p < 0.001) PSM. For HCC 3-5 cm, both OS and RFS significantly improved in the preoperative TACE group, both before (OS: p = 0.038; RFS: p < 0.001) and after (OS: p = 0.038; RFS: p < 0.001) PSM. For HCC > 5 cm, OS was not significantly different but RFS improved in the preoperative TACE group both before (OS: p = 0.42; RFS: p = 0.002) and after (OS: p = 0.42; RFS: p = 0.004) PSM. Additionally, complete lipiodol uptake was associated with better OS (p = 0.032) and RFS (p = 0.045) in tumors 3-5 cm compared with incomplete lipiodol uptake. Multivariate analysis identified preoperative TACE and complete lipiodol uptake as significant factors in improving RFS.
Conclusion: Preoperative TACE, achieved as complete lipiodol uptake as possible, is recommended to prevent postoperative recurrence of resectable solitary HCC, particularly for tumors measuring 3-5 cm, due to the clear survival benefits in both OS and RFS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1245/s10434-025-17257-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predicting tumor response to TACE plus lenvatinib and PD-1 inhibitors for unresectable HCC: A multicenter observational study.
Eur J Radiol
September 2025
Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China. Electronic address:
Objectives: Preoperatively identifying patients with unresectable hepatocellular carcinoma (uHCC) who are likely to achieve an objective response to the treatment regimen of transarterial chemoembolization (TACE) plus lenvatinib and programmed death-1 inhibitors (TLP) remains challenging. We aimed to develop and validate a predictive model for tumor response to TLP treatment in patients with uHCC.
Materials And Methods: Patients with uHCC who received TLP treatment were divided into training (n = 107), internal validation (n = 46), and external validation (n = 52) cohorts.
Using Machine Learning to Predict Advanced-Stage Progression of Intermediate-Stage Hepatocellular Carcinoma after Transarterial Chemoembolization.
Radiol Imaging Cancer
September 2025
Department of Radiation Oncology, Cancer Center, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan Road, Guangzhou, China 510080.
Purpose To develop and test a machine learning (ML)-based model that integrates preoperative variables for prediction of advanced-stage progression (ASP) after transarterial chemoembolization (TACE). Materials and Methods This multicenter retrospective study (ResearchRegistry.com identifier no.
View Article and Find Full Text PDFSimultaneous Portal and Hepatic Vein Embolization versus Portal Vein Embolization Only in Patients with Hepatocellular Carcinoma: A Retrospective Review of Safety and Effectiveness.
J Vasc Interv Radiol
September 2025
Department of Radiology, Hanoi Medical University, Hanoi, Vietnam.
Purpose: To compare the safety and efficacy of simultaneous portal and hepatic vein embolization (PHVE) versus portal vein embolization (PVE) in enhancing future liver remnant (FLR) hypertrophy in patients with hepatocellular carcinoma (HCC).
Materials And Methods: This retrospective study included 97 patients with HCC who underwent transarterial chemoembolization (TACE) followed by PVE (n = 34) or PHVE (n = 63) for preoperative liver augmentation. Volumetric analysis using contrast-enhanced CT was performed at a median of 25 days (PHVE) and 31 days (PVE) post-embolization (P = .
MRI-based radiomics predicts complete responses to initial transcatheter arterial chemoembolization in virus-associated early and intermediate stage HCC.
Magn Reson Imaging
August 2025
The First Affiliated Hospital of China Medical University, PR China. Electronic address:
To evaluate the value of a multiparametric MRI-based nomogram on predicting response to transcatheter arterial chemoembolization (TACE) in virus-associated hepatocellular carcinoma (HCC) patients; METHODS: This study enrolled 235 and 51 patients from Center 1 and 2, respectively. All patients underwent baseline MRI scans before treatment. The least absolute shrinkage and selection operator (LASSO) regression method was used to screen radiomics features from intra- and peri-tumor areas to establish the radiomics signatures (RS).
View Article and Find Full Text PDFCT-based deep learning radiomics model for predicting proliferative hepatocellular carcinoma: application in transarterial chemoembolization and radiofrequency ablation.
BMC Med Imaging
September 2025
Department of Radiology, Tianjin First Central Hospital, Tianjin Institute of Imaging Medicine, School of Medicine, Nankai University, 24 Fukang Road, Nankai District, Tianjin, 300192, China.
Objectives: Proliferative hepatocellular carcinoma (HCC) is an aggressive tumor with varying prognosis depending on the different disease stages and subsequent treatment. This study aims to develop and validate a deep learning radiomics (DLR) model based on contrast-enhanced CT to predict proliferative HCC and to implement risk prediction in patients treated with transarterial chemoembolization (TACE) and radiofrequency ablation (RFA).
Materials And Methods: 312 patients (mean age, 58 years ± 10 [SD]; 261 men and 51 women) with HCC undergoing surgery at two medical centers were included, who were divided into a training set ( = 182), an internal test set ( = 46) and an external test set ( = 84).